Woburn, MA – July 28, 2021 – MBL International, a JSR Life Sciences company, recently announced commercial availability of QuickSwitch™ Class II Custom MHC Tetramer Kits. QuickSwitch kits for Class II MHC Tetramers for analysis of CD4+ T cells have been created to meet the needs of scientists looking for better understanding of the CD4+ T cell responses.
This new QuickSwitch kit combines peptide-MHC Class II quantification and MHC Class II tetramer generation for CD4+ T cell staining. The final custom peptide-exchanged MHC Class II Tetramer created by the researcher does not need to undergo any additional analysis or processing and is ready to use for the next desired application.
It has increasingly been shown that the immune system plays a crucial role in fighting disease progression caused by tumor cells or pathogens such as Influenza. While much attention has traditionally been paid to CD8+ T cell responses, recent reports have also stressed the importance of CD4+ T-cells in various immune response stages. With every new function that is discovered and characterized for CD4+ and CD8+ T cells, we gain valuable understanding for how our immune system works, and how we can “assist” our immune system during disease states.
QuickSwitch kits for Class I MHC Tetramers, which are used for analysis of CD8+ T cells, have been well received and resulted in groundbreaking publications in journals such as Cell and PNAS. In some cases, QuickSwitch kits were used for screening peptides to find strong candidates for further neoantigen investigations. In other cases, QuickSwitch was used to generate tetramers for analyzing antigen specific T cell response resulting from various experimental conditions.
“MHC Class II QuickSwitch kits allow researchers to make multiple custom tetramers and obtain data quickly which is ideal for fast paced research projects,” said Marc Delcommenne, Director of R&D. “Our Class II QuickSwitch specifically targets some of the most popular alleles, including HLA-DRB1*01:01, HLA-DRB1*04:01, and HLA-DRB1*15:01.”
Currently, there are QuickSwitch kits available for four human Class I alleles and one mouse Class I allele. The addition of these three human Class II alleles allows for a more robust portfolio offering for popularly researched alleles in the biological sciences and pharmaceutical sectors. MBL International expects to continue developing additional alleles to add to the QuickSwitch portfolio for future product offerings.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MBL Co-sponsors a Seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID / the 72nd JSC Conference
MBL to co-sponsor a seminar on MEBRIGHT™ genitalium Plus DR Kit at the 98th JAID/72nd JSC Conference, focusing on STD treatment advancements. Learn more on June 27th, 2024.
MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis
MBL has announced that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of...
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
Launch of a New Chemiluminescence Immunoassay Analyzer “iStar500”
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact & integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency ...